354 related articles for article (PubMed ID: 27160225)
1. Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate.
Bergsma H; Konijnenberg MW; van der Zwan WA; Kam BL; Teunissen JJ; Kooij PP; Mauff KA; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1802-11. PubMed ID: 27160225
[TBL] [Abstract][Full Text] [Related]
2. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
Valkema R; Pauwels SA; Kvols LK; Kwekkeboom DJ; Jamar F; de Jong M; Barone R; Walrand S; Kooij PP; Bakker WH; Lasher J; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():83S-91S. PubMed ID: 15653656
[TBL] [Abstract][Full Text] [Related]
4. Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.
Rolleman EJ; Forrer F; Bernard B; Bijster M; Vermeij M; Valkema R; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):763-771. PubMed ID: 17146655
[TBL] [Abstract][Full Text] [Related]
5. Salvage PRRT with
Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
[TBL] [Abstract][Full Text] [Related]
6. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.
Sabet A; Ezziddin K; Pape UF; Reichman K; Haslerud T; Ahmadzadehfar H; Biersack HJ; Nagarajah J; Ezziddin S
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):505-10. PubMed ID: 24196919
[TBL] [Abstract][Full Text] [Related]
7. Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival.
Löser A; Schwarzenböck SM; Heuschkel M; Willenberg HS; Krause BJ; Kurth J
Nucl Med Commun; 2018 Mar; 39(3):236-246. PubMed ID: 29315138
[TBL] [Abstract][Full Text] [Related]
8. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
9. Prospective observational study of
Garske-Román U; Sandström M; Fröss Baron K; Lundin L; Hellman P; Welin S; Johansson S; Khan T; Lundqvist H; Eriksson B; Sundin A; Granberg D
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):970-988. PubMed ID: 29497803
[TBL] [Abstract][Full Text] [Related]
10. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
Barone R; Borson-Chazot F; Valkema R; Walrand S; Chauvin F; Gogou L; Kvols LK; Krenning EP; Jamar F; Pauwels S
J Nucl Med; 2005 Jan; 46 Suppl 1():99S-106S. PubMed ID: 15653658
[TBL] [Abstract][Full Text] [Related]
11. Personalized
Del Prete M; Buteau FA; Beauregard JM
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1490-1500. PubMed ID: 28361189
[TBL] [Abstract][Full Text] [Related]
12. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
[TBL] [Abstract][Full Text] [Related]
13. Long-term toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats.
Rolleman EJ; Krenning EP; Bernard BF; de Visser M; Bijster M; Visser TJ; Vermeij M; Lindemans J; de Jong M
Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):219-27. PubMed ID: 17021812
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
15. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
Gupta SK; Singla S; Bal C
Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
[TBL] [Abstract][Full Text] [Related]
16. Long-term Nephrotoxicity after PRRT: Myth or Reality.
Baum RP; Fan X; Jakobsson V; Yu F; Schuchardt C; Chen X; Zhang J
Theranostics; 2024; 14(2):451-459. PubMed ID: 38169589
[No Abstract] [Full Text] [Related]
17. Dynamic and static small-animal SPECT in rats for monitoring renal function after 177Lu-labeled Tyr3-octreotate radionuclide therapy.
Melis M; de Swart J; de Visser M; Berndsen SC; Koelewijn S; Valkema R; Boerman OC; Krenning EP; de Jong M
J Nucl Med; 2010 Dec; 51(12):1962-8. PubMed ID: 21078795
[TBL] [Abstract][Full Text] [Related]
18. Early prediction of tumour response to PRRT. The sequential change of tumour-absorbed doses during treatment with 177Lu-octreotate.
Ezziddin S; Reichmann K; Yong-Hing C; Damm M; Risse J; Ahmadzadehfar H; Logvinski T; Guhlke S; Biersack HJ; Sabet A
Nuklearmedizin; 2013; 52(5):170-7. PubMed ID: 23963021
[TBL] [Abstract][Full Text] [Related]
19. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
Ranade R; Basu S
J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
[TBL] [Abstract][Full Text] [Related]
20. Renal function affects absorbed dose to the kidneys and haematological toxicity during ¹⁷⁷Lu-DOTATATE treatment.
Svensson J; Berg G; Wängberg B; Larsson M; Forssell-Aronsson E; Bernhardt P
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):947-55. PubMed ID: 25655484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
